Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.54 |
| ▸ | FASN | P49327 | 16/20 | 0.50 |
| ▸ | QDPR | P09417 | 2/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13262763 | 0.82 | RET (0.53) | USP30FASN | |
| SCHEMBL17395592 | 0.81 | QDPR (0.60) | QDPR | |
| SCHEMBL12478958 | 0.80 | QDPR (0.48) | FASNQDPR | |
| SCHEMBL15112858 | 0.80 | USP30 (0.47) | USP30FASN | |
| SCHEMBL18432585 | 0.80 | FASN (0.52) | FASN | |
| SCHEMBL3670130 | 0.79 | AR (0.48) | USP30 | |
| SCHEMBL23858337 | 0.78 | QDPR (0.60) | FASNQDPR | |
| SCHEMBL12488646 | 0.78 | SCD5 (0.53) | USP30FASNSCD5 | |
| SCHEMBL17397793 | 0.78 | QDPR (0.46) | USP30FASNQDPR | |
| SCHEMBL212891 | 0.78 | QDPR (0.46) | FASNQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | USP30 4370/4885FASN 2365/4885QDPR 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.